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Neo-LVOT and Transcatheter Mitral
Valve Replacement
Expert Recommendations
Anna Reid, MBCHB,a,* Sagit Ben Zekry, MD,a,* Mansi Turaga, MBCHB,a Stephanie Tarazi, BSC,a Jeroen J. Bax, MD,b
Dee Dee Wang, MD,c Nicolo Piazza, MD,d Vinayak N. Bapat, MBBS,e Abdul-Rahman Ihdayhid, MBBS, PHD,a
João L. Cavalcante, MD,f Philipp Blanke, MD,a Jonathon Leipsic, MDa

ABSTRACT
With the advent of transcatheter mitral valve replacement (TMVR), the concept of the neo–left ventricular outﬂow tract
(LVOT) was introduced and remains an essential component of treatment planning. This paper describes the LVOT
anatomy and provides a step-by-step computed tomography methodology to segment and measure the neo-LVOT while
discussing the current evidence and outstanding challenges. It also discusses the technical and hemodynamic factors that
play a major role in assessing the neo-LVOT. A summary of expert-based recommendations about the overall risk of LVOT
obstruction in different scenarios is presented along with the currently available methods to reduce the risk of LVOT
obstruction and other post-procedural complications. (J Am Coll Cardiol Img 2020;-:-–-) © 2020 by the American
College of Cardiology Foundation.

M

itral regurgitation is highly prevalent, re-

TMVR also includes previously approved trans-

ported in almost 10% of patients >75

catheter aortic valve replacement (TAVR) valves for

years of age (1), with at least one-half of

use in the mitral space, principally for use in valve-in-

these patients are not suitable for surgical interven-

valve (ViV), valve-in-ring (ViR), or valve-in-mitral

tion given comorbidities. Left untreated, 90% of

annulus calciﬁcation (ViMAC).

these will experience at least 1 heart failure hospital-

The structure and function of the mitral valve is

ization, with a mortality rate of 50% within 5 years

complex,

(2,3). Thus, transcatheter mitral valve replacement

annulus, variable leaﬂet lengths and heights, and

comprising

a

nonplanar,

noncircular

(TMVR) has gained much interest as a new, less inva-

heterogeneous anatomy of the subvalvular appa-

sive treatment option for patients with signiﬁcant

ratus. These lie in close proximity to adjacent

mitral regurgitation and high surgical risk (4–6).

anatomic structures such as the left circumﬂex artery

In addition to numerous clinical trials and devices

and the left ventricular outﬂow tract (LVOT). Funda-

speciﬁcally designed for the native mitral space (4–6),

mental to TMVR procedural success is a valve
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ABBREVIATIONS

prosthesis that allows for adequate anchoring

because of the potential of ﬁxed obstruction post–

AND ACRONYMS

and sealing, while being able to accommo-

device implantation. Contrary to open-cell technol-

date the dynamic deformation of the mitral

ogy, in which leaﬂets open and close, allowing blood

annulus during the cardiac cycle (7,8). Such a

ﬂow into the LVOT during systole, closed-cell TMVR

device, however, carries a risk of narrowing

devices created a ﬁxed LVOTO, with the depth of

angiography

the LVOT and displacing the native anterior

protrusion of the prosthetic valve into the LVOT be-

LV = left ventricle/ventricular

mitral valve leaﬂet (AML), resulting in LVOT

ing the main predictor of obstruction (12). The risk of

obstruction

Historically,

LVOTO post-TMVR is greater in the presence of an

tract

LVOTO has been considered a rare but

elongated native AML, which can produce dynamic

LVOTO = left ventricular

recognized complication following surgical

LVOTO due to systolic anterior motion of the AML

outﬂow tract obstruction

mitral valve interventions in cases in which

(Figure 2).

MAC = mitral annular

the AML is preserved, or in which the surgical

Acute LVOTO can be a catastrophic complication

calciﬁcation

valve was positioned with the stent post

occurring immediately following TMVR, causing he-

MVARC = Mitral Valve

angulated toward the LVOT. TMVR-related

modynamic collapse and potential periprocedural

LVOTO, however, is feared and is poten-

death (10). More chronic LVOTO may also be seen as a

tially fatal, and is reported in approximately

consequence of LV reverse remodeling after mitral

7% to 9% of TMVR procedures (7). For these

regurgitation correction, and patients are typically

reasons, and building on experience with

preload dependent and sensitive to volume changes.

transcatheter

Chronic LVOTO increases LV afterload and may

AML = anterior mitral valve
leaﬂet

CTA = computed tomography

LVOT = left ventricular outﬂow

Academic Research Consortium

TAVR = transcatheter aortic
valve replacement

TMVR = transcatheter mitral
valve replacement

ViMAC = valve-in-mitral

(LVOTO)

aortic

(9,10).

valve

implantation,

annular calciﬁcation

contrast-enhanced

multiphasic

computed

introduce adverse hypertrophic LV remodeling, pre-

ViR = valve-in-ring

tomography angiography (CTA) has quickly

disposing to subsequent ventricular failure, particu-

ViV = valve-in-valve

become embedded as an essential comple-

larly in the context of underlying LV dysfunction (13).

mentary tool in treatment planning, device
selection, and patient-speciﬁc procedural risk stratiﬁcation prior to TMVR (8,9). Given that threatened
LVOTO is an exclusion criteria for approximately 50%
of patients in contemporary clinical trials (10), our
capability

for

accurate

modelling

of

the

post-

procedure neo-LVOT with CTA is crucial for procedural success. This document aims to provide practical recommendations for current protocols and
techniques used in the assessment of risk of LVOTO
post-TMVR (Central Illustration).

SEGMENTATION
NEO-LVOT. Given

AND

the

MEASUREMENT

dynamicity

and

OF

THE

complex

interplay of the mitral prosthesis, LVOT, and LV in
the generation of neo-LVOTO, contrast-enhanced
CTA data acquisition should cover the entire systolic
cardiac cycle, either by means of retrospectively
electrocardiography-gated data acquisition, or by
prospective

electrocardiography-triggered

data

acquisition with “whole-heart” detector coverage.
Datasets should be reconstructed at minimum of 10%
R-R interval (preferably at 5% of R-R intervals [i.e., 20

THE CONCEPT OF THE NEO-LVOT

phases]), and optimally without dose modulation.
Presence of atrial ﬁbrillation or faster heart rates can

ANATOMY OF THE NATIVE LVOT AND THE NEO-LVOT.

compromise data quality, and absolute millisecond

The native LVOT is the anatomic tract conﬁned by the

reconstruction at 50-ms intervals can improve image

region of potential interaction between a proposed

quality when compared with % of R-R intervals.

implanted device and the opposing basal to mid

A 3-step method for neo-LVOT measurement in

anteroseptal wall of the LV (Figure 1). TMVR devices

native mitral valve disease is described in detail in

comprise fabric-covered stent struts that protrude

Figure 3. Methods of segmentation of the native

into the basal LV cavity. After implantation, the

D-shaped mitral valve annulus using CTA have been

TMVR pins the native AML open, displacing it toward

comprehensively described previously. In brief, the

the septum, thereby creating a “neo-LVOT,” conﬁned

D-shaped annulus is formed by truncating the

by the displaced AML, the stent of the TMVR, and the

anterior horn from the saddle-shaped annulus at

basal-mid anteroseptal LV wall (11), similar in concept

the level of the ﬁbrous trigones, facilitating and

to “ﬁxed” systolic anterior motion of the mitral valve.

standardizing the sizing for TMVR. Typically, pre-

Implantation of an artiﬁcial valve into a native

TMVR, 3-dimensional segmentation of the mitral

mitral annulus landing zone decreases the available

annulus is performed in end-diastole by measuring

surface area for blood to ﬂow into the patient’s native

the intersection of the left atrium and LV blood ﬂow,

LVOT. In the transcatheter world, implantation of a

commonly identiﬁed by the basal insertion points of

closed-cell TMVR device necessitates an in-depth

the anterior and posterior mitral leaﬂets. Post-

understanding

processing provides the annular area and perimeter,

of

the

entire

threatened

LVOT,
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C ENTR AL I LL U STRA T I O N Key Elements of Computed Tomography Acquisition and Evaluation
for Neo-LVOT Obstruction Risk During Transcatheter Mitral Valve Replacement
• LVOT peak gradient >10 mm Hg from
baseline echocardiography
• Peak gradient >30 mm Hg. Haemodynamically
significant >50 mm Hg
• LVOT Area <1.7-1.9 cm2

• Small Ventricle
• Asymmetrical septal hypertrophy
• Perpendicular aorto-mitral angulation
• Elongated anterior leaflet
• Device related

Anatomic definition of Neo-LVOT

Hemodynamic Definition
of LVOT Obstruction

Anatomic High-risk
Consideration
LV
OT

Neo-LVOT

Prosthetic Valve

Anatomic Segmentation of Neo-LVOT

Native
CT Acquisition

• Full Cardiac Cycle
• Data Set Reconstruction of 5-10%
Interval
• Mid to End Systole Phase
Reconstruction

Bioprosthetic

1
2

Ring
SL

3

IO
Pe.

2
1

Reid, A. et al. J Am Coll Cardiol Img. 2020;-(-):-–-.

Approach to computed tomography imaging and analysis for left ventricular outﬂow tract (LVOT) obstruction during transcatheter mitral
valve replacement.

and major and minor dimensions. This step can be

HEMODYNAMIC DEFINITION OF LVOTO POST-TMVR.

done with standard post-processing CTA software (8).

The upper bound for acceptable LVOT gradients post-

This same segmentation is repeated in mid- or end-

TMVR has not yet been deﬁned. According to the

systole, which serves as the anatomic landmark for

Mitral

CTA-based virtual simulation of device implantation,

(MVARC) criteria, surgical device–related, iatrogenic

Valve

Academic

Research

Consortium

by embedding either a device-speciﬁc contour (using

LVOTO is deﬁned as an increment in peak LVOT

a stereolithographic ﬁle) or a generic cylindrical or D-

gradient of >10 mm Hg from baseline, derived from

shaped contour. The minimal cross-sectional area of

echocardiography (14). Varying thresholds of peak

the neo-LVOT at the site of the greatest encroachment

LVOT gradient post-TMVR have been proposed. In

and narrowing can be planimetered using a multi-

clinical trials evaluating novel investigational TMVR

planar reformat plane orthogonal to a centerline

devices not yet approved for commercial implanta-

plotted through the LVOT. This step requires a dedi-

tion, the general accepted deﬁnition for early signs of

cated TMVR modulus, which allows the simulation of

LVOTO and gradient adhere to MVARC recommen-

the residual neo-LVOT, while accounting for the

dations of 10 mm Hg. In patient populations at risk of

prosthesis characteristics.

critical LVOTO who are ineligible for investigational
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most important factor to inﬂuence the pressure

F I G U R E 1 Chamber Reconstruction of a Cardiac Computed Tomography

gradient. Pre-procedural estimation of the neo-LVOT

Angiogram Deﬁning the Anatomical Neo-LVOT

area is therefore a fundamental aspect of the
patient-speciﬁc risk stratiﬁcation, but uncertainties

A

still exist. The lack of early prospective and TMVRspeciﬁc data generated a reliance on extrapolated
hypertrophic obstructive cardiomyopathy data to
derive conservative consensus threshold of a minimal
neo-LVOT cross-sectional area of 2 cm2 in mid-systole

LV
OT

4

R

Neo-LVOT

L

(20), which has been used in several clinical trials but
has resulted in high rates of screening failure and
ineligibility for TMVR (10).
The current TMVR literature comprises small,

Prosthetic Values

heterogeneous studies, including a mixed population
of patients undergoing TMVR for native valve dis-

P

ease, failed surgical replacements or repair, and
calciﬁc mitral valve disease. Nevertheless, these data
have allowed for the validation of the technique by
demonstrating

The left ventricular outﬂow tract (LVOT) is deﬁned by the basal-mid
anteroseptal wall and the mitral intervalvular ﬁbrosa (orange dotted line).

excellent

correlation

between

predicted and with actual neo-LVOT area on postprocedural

CTA

left ventricular cavity (green dotted line) to produce the neo-LVOT

procedural

simulated

(red dotted line).

shown correlate with post-procedural adverse clinical

Following valve placement, the prosthetic valve is protruding into the basal

(17).

Furthermore,
neo-LVOT

area

small

pre-

has

been

outcomes (17). Despite this, the threshold for the
smallest neo-LVOT area that will generate acceptable
post-implantation outcomes and gradients has been
TMVR devices due to complex anatomy (i.e., off-label

challenging to establish and likely not as dichoto-

use of commercially available devices such as the

mous

Edwards SAPIEN transcatheter heart valve [Edwards

neo-LVOT area of 1.7 to 1.9 cm2 have been demon-

Lifesciences, Irvine, California]) LVOTO has been

strated to predict LVOTO according to MVARC

proposed as a peak gradient of >30 mm Hg, with he-

criteria, with high sensitivities and speciﬁcities, but it

modynamically signiﬁcant LVOTO as a peak gradient

is important to note that these studies used different

of >50 mm Hg (15). To date, there is no consensus.

TMVR technologies (17,21). Current neo-LVOT cutoffs

Early technologies have demonstrated the presence

of 1.7 to 1.9 cm2 have largely been studied on closed

of potential positive and negative LVOT remodeling

cell-TMVR technologies such as the Edwards SAPIEN

post–TMVR device implantation. Our understanding

3 and Tendyne (Tendyne, Roseville, Minnesota)

of clinically relevant obstruction being >30 mm Hg

valves. This neo-LVOT cut-off is not yet well under-

has been inferred from data deﬁned in the setting of

stood for hybrid cell technologies including the Evo-

hypertrophic obstructive cardiomyopathy, and the

que

ability to apply this in a dynamically remodeling LV in

Lifesciences) where there is an open frame docking

the TMVR population is not yet well studied (16).

system external to an internal closed valve design.

and

and

binary

as

Medtronic

proposed.

Apollo

Thresholds

device

of

(Edwards

There is an inverse correlation between LVOT

Furthermore, mid-systolic neo-LVOT area is not the

gradient and neo-LVOT area post-TMVR (17). Inter-

sole determinant of LVOTO, and more thoughtful

estingly, computational models using CT datasets,

integration of ventricular and device geometry, as

facilitating simulation of different virtual valves and

well as LV function and AML, are required.

LVOT ﬂows, conﬁrm the relationship between LVOT
area and pressure gradient in TMVR. A reduction of

KEY CONSIDERATIONS IN THE ASSESSMENT

35% in LVOT area has been shown to generate expo-

OF THE NEO-LVOT AREA

nential increases in LVOT pressure gradients and
reduced LV emptying, inducing low cardiac output

PHASE SELECTION. Both the native mitral valve

(18). The ﬁnding of a nonlinear relationship between

complex (leaﬂet, annulus, and subvalvular apparatus)

neo-LVOT area and pressure gradient has been sup-

and neo-LVOT are dynamic structures, changing size

ported by other computational models. Alharbi et al.

and shape throughout the cardiac cycle. Echocardio-

(19) recently conﬁrmed that the neo-LVOT area is the

graphic and CTA-derived data identify the LVOT area
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F I G U R E 2 Echocardiographic Evaluation of Dynamic LVOT Obstruction

A

B

C

D

An example of dynamic left ventricular outﬂow tract (LVOT) obstruction. Following transcatheter mitral valve replacement, there is systolic
anterior motion of the residual native anterior mitral leaﬂet (arrow) as demonstrated in (A) computed tomography and (B, C) 2-dimensional
echocardiography. (D) The resulted dynamic LVOT obstruction is seen with the LVOT continuous-wave Doppler.

as being smallest at end-systole. However, there is

In the Intrepid Global Pilot Study cohort, Meduri

confusion in terminology between echocardiographic

et al. (22) identiﬁed that pre-procedural end-systolic

and CTA datasets. Owing to the inherent delay

prediction of neo-LVOT area was found to be smaller

between electrocardiography sensing and echocar-

than

diographic contract, the end-systole on a parasternal

(in ascending size) at end-systole, multiphasic, and

long-axis view of the LV most commonly correlates to

early systole. This study emphasized the importance of

55%, or early diastole on CTA. CTA does not suffer

understanding TMVR device technology and potential

from electrocardiography sensing delays long docu-

presence or absence of device conformational changes

mented in echocardiography, although the timing of

with relation to the patient’s native mitral annulus. In

phase reconstruction does vary across vendors,

the presence or absence of TMVR device deformation,

meaning 50% of the R-R interval is not the same thing

there would be potentially associated neo-LVOT

across CT scan platforms. Safe TMVR planning must

prediction modeling changes that would need to be

include an understanding of the dynamism of the

accounted for. Additionally, multiphasic and early

structures within the LVOT during systole. LV cavity

systolic neo-LVOT allowed better discrimination of

size as a sole indicator of phase selection is addi-

post-procedure LVOT gradient and better prediction of

tionally not an adequate predictor of neo-LVOT risk,

the post-procedure neo-LVOT, with the added poten-

the

true

post-procedure

neo-LVOT

area

as early diastole is commonly when LV volume is

tial for increasing eligibility for TMVR (22). It is

smaller on CTA and echocardiography. Safety checks

essential to recognize that the majority of patient

must be employed to ensure that in systolic phases

screening to date has relied on adjudication of the

the aortic valve is open, and not closed, as physio-

neo-LVOT in mid- and end-systole, and while

logically, in a nondiseased aortic valve, systole is

hypothesis generating, the recent work with the

deﬁned as the phase when the valve is open.

Intrepid device may be device speciﬁc, and there is not
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F I G U R E 3 Stepwise Approach to Neo-LVOT Segmentation in Native Mitral Regurgitation With CT

Step & Description
Step 1: Multipoint segmentation of the D-shaped
native mitral valve annulus, as previously described
(15). Annulus size (area, septolateral [SL], and
intercommissural [IC] distance) is used to determine
eligibility for, and sizing of the transcatheter mitral
valve replacement.

Step 2: Virtual implantation of TMVR (here a
Tendyne device is modelled, and shown in
3-chamber, short axis, and 4-chamber). The device
size can be manually adjusted.

Step 3: Segmentation of the neoLVOT using a
centreline technique. The center line is manuaIly
drawn, following the trajectory of the LVOT (orange
Iine). The neo-LVOT is visually interrogated using the
green slider. The smalIest neo-LVOT area (curved
orange dotted line) can then be measured (6.5 cm2
in this case).

IC ¼ intercommisure; LVOT ¼ left ventricular outﬂow tract; SL ¼ septolateral; TMVR ¼ transcatheter mitral valve replacement.

enough evidence to transition to early systolic mea-

conceptually, small end-systolic LV dimensions are

surements for risk prediction. This work does also

likely to predict neo-LVOTO and thus obviate the

emphasize the need to improve our pre-procedural

need for time-consuming image post-processing (25).

measurements by learning from post-TMVR CTA

Mitral valve and chordal anatomy vary between

datasets, which are invaluable to reﬁne our under-

patients but is an important consideration in the

standing of device-speciﬁc post-implant remodeling

prediction of LVOTO. An elongated AML with

and its impact on the neo-LVOT geometry.

redundant chordae is an accepted risk factor for

ANATOMICAL HIGH-RISK FEATURES. LVOT area is

dynamic LVOTO, although there are no currently

affected by LV size, thickness, right ventricular size,

accepted thresholds (26). The current available TMVR

function, dynamism, and loading conditions. Previ-

simulation software do not account for the residual

ous studies of patients following surgical mitral valve

AML, which can protrude toward the neo-LVOT,

replacement have shown that LVOT area and the risk

causing dynamic LVOTO. Bulky calciﬁcation in the

of LVOTO is increased in patients with small, hyper-

AML has the potential to displace the LVOT following

contractile LV as well as with the presence of septal

valve placement (27). Native mitral annular dynam-

hypertrophy

bulge

icity inﬂuences LVOT area throughout the cardiac

(>15 mm) (16,18,20,23,24). Similar physiology is

cycle; however, this is lost following prosthetic valve

anticipated in TMVR. It is, of course, impossible to

implantation. Thus, the current method of neo-LVOT

completely predict and incorporate a patient’s phys-

area analysis still has room for improvements.

or

an

asymmetrical

septal

iologic response to a TMVR insertion, changes in their

Aortomitral angulation describes the angle be-

cardiac output once the degree of mitral regurgitation

tween the annular planes of the aortic and mitral

is reduced, and the degree of the post-procedural LV

valve and is typically measured in end-systole.

remodeling and changes in dynamism into the pre-

Conceptually, a mitral annular trajectory (and there-

procedural risk assessment of LVOTO. However,

fore TMVR trajectory) running parallel to the LVOT
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long axis would result in minimal risk of LVOTO,

may not inﬂuence the neo-LVOT area but may inﬂu-

whereas a perpendicular orientation, and subsequent

ence the ability to achieve adequate skirt–neo-LVOT

canting of the TMVR trajectory toward the septum,

area in high-risk patient populations requiring the

would result in maximal risk. It is recommended that

LAMPOON procedure. Bench testing indicates a ten-

aortomitral angulation is considered together with

dency of porcine valve leaﬂets to crumple, compared

LVOT, septal, and LV geometry, rather than as a sin-

with pericardial valve leaﬂets, which remain rigid and

gle, stand-alone factor. The importance of the aorto-

upright. Pericardial valve leaﬂets are also longer, and

mitral angle more commonly affects valve depth

therefore likely to cover more surface area of the

deployment, valve coaxiality, and feasibility of

TMVR stent. These are, then, conceptually more

different transcatheter or surgical approaches to

likely to form a covered cylindrical stent and

maximize

Furthermore,

neo-LVOTO (12). A method for neo-LVOT area using

quantiﬁcation may be limited by subjective assess-

double oblique, multiplanar reformation is described

ment of the LVOT long axis, although facilitated

in Figure 4. Alternatively, dedicated software with

workﬂows may improve this observer variability (8).

virtual

LVOT

area

post-TMVR.

DEVICE FEATURES. The varying features of individ-

ual TMVR prosthesis plays a key role in estimation of
the neo-LVOT. The currently available devices have
different structures, which is outside the scope of this
paper, but in general, the greater the depth of device
protrusion into the LV and extent of device ﬂaring at
LVOT level will lead to narrower and smaller
neo-LVOT area (11,12). Moreover, it is currently
impossible to predict the end position and shape of
the implant, and the degree of compression the
device will undergo, particularly in nitinol-based
devices. For this reason, in borderline cases, the
true neo-LVOT area may be larger (if greater
compression occurs) or smaller (if there is signiﬁcant
LV protrusion) than that predicted.

LVOT OBSTRUCTION RISK IN SPECIFIC
PATIENT POPULATIONS

valve

implantation

may

be

performed

(Figure 5). Measurements of the surgical prosthesis
should be performed to conﬁrm the surgical report
and be done along the inner border, taking care to
optimize image acquisition (using body size appropriate tube voltage and tube current), image reconstruction (using thin slices and without cardiac
motion), and wide grayscale display settings to
minimize beam hardening and blooming artifacts.
Similar to ViV, mitral ViR is performed using a
transcatheter aortic valve (Figure 6); however, ViR is
associated with relatively higher rates of LVOTO,
occurring in 5% to 8% of procedures (28,30,31).
Longer AML length appears to be a particularly relevant anatomic risk factor for LVOTO; further study
and integration of other anatomic and procedural risk
factors are likely to be required to deﬁne speciﬁc
thresholds.
Conceivably, the type of previous annuloplasty
ring affects the degree of risk of LVOTO in ViR cases

MITRAL ViV AND ViR. In the context of a failing

(28). Rigid rings do not allow for full expansion of the

bioprosthesis, mitral ViV implantation is typically

percutaneous valve; instead, the valve deforms to ﬁt

performed with a transcatheter aortic valve into the

the oval shape of the ring, risking valve malfunction.

mitral position. The risk of neo-LVOTO in this group

By contrast, ﬂexible and semi-rigid rings will conform

is higher than that compared with native TMVR,

to match the circular shape of the percutaneous

occurring in 2.2% to 2.6% of cases (17,28). The new

valve. While preferred for valve function, ViR dis-

prosthesis pins the failing valve leaﬂets open, envel-

places the AML toward the LVOT and septum, thereby

oping the open valve stent cells of the TMVR, and

increasing the risk of LVOTO (32,33). Recent data,

creating a covered cylinder which may induce a ﬁxed

however,

obstruction (12,28). Risk of neo-LVOTO may vary

amongst the varying ring types, but in small numbers

depending on the intrinsic features of the original

(31). Last, it bears repeating that current TMVR

implant. Because the failing leaﬂets will only extend

simulation software for the ViR TMVR procedure do

at most to the tip of the original stent posts, the

not account for the residual AML, which can protrude

height, rather than size, of the failing prosthesis is an

toward the neo-LVOT, causing dynamic LVOTO.

identiﬁed

no

difference

in

outcomes

important factor in determining the risk of neo-LVOT

Common to both procedures is the interplay be-

anatomy and obstruction. Canting of the surgical

tween the sewing ring annular plane and LV. Recent

valve toward the septum, as opposed to parallel, may

published data suggest that in addition to an antici-

also predispose to neo-LVOTO (12,29). Orientation of

pated neo-LVOT area of <1.9 cm 2, an annulus-to-

the stent struts within the native mitral valve annulus

septal distance of <17.8 mm, an LV end-diastolic
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F I G U R E 4 Stepwise Approach to Neo-LVOT Segmentation in the Setting of a Bioprosthetic Mitral Valve

Step 1: Starting with multi-planar images in the
default axial (red box), sagittal (green box) and
coronal (blue box) orientation, center the crosshairs onto the center of the mitral valve.

Step 2: Rotate the cross-hairs in the axial and
sagittal views to intersect the LV apex and align
with the long axis of the left ventricle to depict
a double oblique short axis view of the sewing
ring of the surgical valve prosthesis.
Step 3: Rotate the crosshairs clockwise on the
short axis plane of the valve prosthesis to
intersect the aortic valve and run parallel to the
aortic root. This will generate a 3-chamber view
in the formally axial view (red box).
Step 4: Increase the maximal intensity
projection to visualise the three stent posts of
the valve prosthesis in the long axis views
(orange arrows).

Step 5: On the 3-chamber view, position and
align the crosshairs on the intersection of the
level stent post tips and septal edge of the
prosthesis (yellow arrow). The dashed rectangle
represents the conceptual prosthesis 'space'.
Step 6: Rotate the crosshairs clockwise in the
3-chamber view to align with the LVOT
trajectory.

Step 7: Reduce the maximal intensity projection
to visualize the LVOT in short axis (yellow arrow,
blue box).

Step 8: Zoom in to optimize the working view.

Step 9: The neoLVOT area can be planimetered.
The center of the crosshair represents the most
distal point of the septal aspect of the
prosthesis, which will form the inferior border
of the neo-LVOT (yellow dashed line).

LV ¼ left ventricle; LVOT ¼ left ventricular outﬂow tract.
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F I G U R E 5 Stepwise Approach to Neo-LVOT Segmentation in the Setting of a Mitral Bio-Prosthesis

Step & Description
Step 1: Segmentation of the prosthetic valve basal
ring. A 31mm Magna was segmented in mid-late
systole (40% in this case). The true internal
diameter (measured with the automatically
generated SL or Ie dimension) was 28.5 mm.

Step 2: Virtual implantation of a TMVR. A 29mm
Sapien S3 was modelled, and offset to the level of
the stent posts (yellow arrows).

Step 3: Segmentation of the neo-LVOT. The
center line is manually drawn as in native valves. The
smallest neo-LVOT area was measured as 4.2 cm2 in
this case.
1
2

LVOT ¼ left ventricular outﬂow tract; TMVR ¼ transcatheter mitral valve replacement.

dimension of <48 mm, LV mass index >105 g/m 2, and

(32) post-TMVR for TMVR ViMAC. Compared with ViV

relative wall thickness of >0.38 convey increased risk

and ViR, procedural mortality after LVOTO has been

of neo-LVOTO (17). Validation of these thresholds in a

reported to be as high as 45% in ViMAC (17).

larger cohort of patients is required.

The cause of LVOTO in this group is multifactorial. It

Procedurally, transcatheter heart valves are gener-

has been described that intrinsically, severe posterior

ally oversized to reduce the risk of valve embolization

MAC can push the mitral valve coaptation point atrial

and paravalvular leak. The resultant ﬂaring should be

and anteriorly, which along with AML then causes

taken into consideration during the pre-procedural

LVOTO (34). Other studies have reported that systolic

imaging assessment; however, this is challenging to

anterior motion of the AML also causes LVOTO in these

do quantitatively. Larger and longer transcatheter

patients (35). Furthermore, MAC is highly heteroge-

heart valves, with deep implantation into the LVOT,

neous, and prediction the ﬁnal positioning of the

will likely decrease the neo-LVOT area (20). The ﬁeld is

TMVR device (in most cases, Edwards SAPIEN 3 TAVR

in need for TMVR-speciﬁc devices for ViV and ViR,

device has been used) is difﬁcult to predict, and the

other than balloon-expandable TAVR devices.

current method of prediction also does not account for

VALVE-IN-MAC. LVOTO is the most important and

the dynamic interaction of the prosthesis and MAC, as

independent predictor of 30-day and 1-year mortality

there is insufﬁcient data to date with regard to the
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F I G U R E 6 Computed Tomography Angiographic Evaluation of the Risk of LVOT Obstruction in Mitral Valve in Ring

IC
Pe.
A

SL

B

2
3
1

C

D

An 80-year-old patient presented with recurrent severe mitral regurgitation, 5 years after mitral valve repair with a 26-mm CE Physio mitral
annuloplasty ring. (A) Annuloplasty ring segmentation was consistent with the manufacturer’s sizing, the internal dimension was 24.6 mm,
and septolateral (SL) dimension was 17 mm. (B) A 3-dimensional rendering of the annuloplasty ring demonstrating segmentation of the inner
rim, which may be difﬁcult to determine because of blooming artifact. Virtual implantation of a 23-mm circular valve with 15% atrial offset
was (C) applied and (D) a neo–left ventricular outﬂow tract (LVOT) area of 4.1 cm2 was measured, indicating low risk of neo-LVOT
obstruction. IC ¼ intercommissure; Pe ¼ perimeter.

deformation of the MAC with radial stress (36). Pa-

LVOTO, pre-procedural alcohol septal ablation has

tients with severe MAC are typically older, with

also been proposed as a potential therapeutic strat-

concomitant cardiac diseases such as aortic stenosis,

egy, similar to its use in patients with obstructive

hypertension, and renal dysfunction, all of which

hypertrophic cardiomyopathy (39). The Achilles heel

predispose the unfavorable anatomic and functional

of this technology is an increased incidence of

characteristics such as small, hyperdynamic LVs with

requirement for permanent pacemaker implantation

LV hypertrophy (37,38).

after alcohol septal ablation, the obligatory 2-week
wait time for the LV basal anteroseptum to remodel,

FUTURE DIRECTIONS

and the risk that patients may have appropriate target
vessels for Alcohol Septal Ablation. Historically, in

To reduce the risk of LVOTO, various surgical and

this patient population, the LAMPOON technology

transcatheter methods have been proposed. Given

was developed, with intention to lacerate the AML as

that basal

important

an adjunct to decrease the risk of LVOTO in this pa-

contributing risk factor in the development of

tient population By lacerating the native AML using

septal hypertrophy is

an
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F I G U R E 7 Computed Tomography Assessment of the Skirt Neo-LVOT

B

A

C

The same patient from Figure 6 is presented to demonstrate the concept of the skirt neo-LVOT. (A) An Edwards SAPIEN 3 valve, with the
fabric skirt identiﬁed by the red arrows and blue dotted line. (B) This valve is then modeled as per Figure 6. The blue dotted line and red
arrows again represent the level of the skirt on the model. (C) If LAMPOON were performed, with laceration to the level of the skirt, the neo–
left ventricular outﬂow tract (LVOT) area at this level would be 5.0 cm2.

an electriﬁed wire that traverses the leaﬂet, the cells

There is much to learn in the TMVR space. Three-

of the “unskirted” portion of the TAVR are exposed,

dimensional printing of anatomic models for neo-

allowing blood to ﬂow across, thereby increasing the

LVOT evaluation have also been demonstrated, but

size of the neo-LVOT. The anticipated “skirt neo-

these are limited, of course, by their ﬁxed anatomy,

LVOT” can again be modelled pre-procedurally

high costs, and the lack of printing materials that

(Figure 7) (26). The limitations of this procedure

mimic human tissue (41). Patient-speciﬁc computer-

include the understanding that it is technically chal-

ized models of computational ﬂuid dynamics are

lenging both from an interventional and imaging

under investigation (39), with the anticipation that

intraprocedural skillset, and is not feasible in calciﬁc

that they may overcome the limitation of a purely

leaﬂets, and may not completely resolve neo-LVOTO

geometric

caused by the fabric skirt. Teams will need to

element models of the heart, both mechanical and

be ready for bail-out alcohol septal ablation if insuf-

geometric properties of the valve and the heart can be

analysis.

Using

3-dimensional

ﬁnite

ﬁcient laceration of the AML occurs on the table.

applied to predict LVOTO (39). Further study will be

Given these limitations, newer technology is being

required to determine the role of these approaches

evaluated looking at preemptive radiofrequency

across a wider spectrum of patients requiring TMVR.

septal ablation to decrease the risk of LVOTO post-

Improved valve design includes lower proﬁles, in-

TMVR (40).

cludes anterior leaﬂet capture, and allows for more
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TMVR, with careful measurement of the neo-LVOT

HIGHLIGHTS

area, which remains one of the most important pre-

 TMVR is increasingly becoming more
common.
 Neo-LVOT is a concept that was introduced to describe the residual LVOT area
created after the implanted transcatheter
mitral valve prosthesis.
 Measurement of the neo-LVOT is
explained and step-by-step process is
proposed.

dictors for iatrogenic LVOTO (Central Illustration).
Further reﬁnement of the methodology through the
integration of post-TMVR CTA imaging in expanding
patient

populations,

with

longer-term

outcome

data, is essential to enhance patient selection and
simulation methodology, and to improve procedural
outcomes.
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